Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Cash & Current Investments: 2017-2025

Historic Cash & Current Investments for Dianthus Therapeutics (DNTH) over the last 8 years, with Sep 2025 value amounting to $402.6 million.

  • Dianthus Therapeutics' Cash & Current Investments rose 43.22% to $402.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 billion, marking a year-over-year increase of 0.49%. This contributed to the annual value of $275.2 million for FY2024, which is 58.44% up from last year.
  • Latest data reveals that Dianthus Therapeutics reported Cash & Current Investments of $402.6 million as of Q3 2025, which was up 56.42% from $257.4 million recorded in Q2 2025.
  • In the past 5 years, Dianthus Therapeutics' Cash & Current Investments ranged from a high of $402.6 million in Q3 2025 and a low of $52.9 million during Q1 2023.
  • For the 3-year period, Dianthus Therapeutics' Cash & Current Investments averaged around $244.5 million, with its median value being $263.2 million (2025).
  • In the last 5 years, Dianthus Therapeutics' Cash & Current Investments crashed by 66.22% in 2023 and then soared by 612.80% in 2024.
  • Over the past 4 years, Dianthus Therapeutics' Cash & Current Investments (Quarterly) stood at $75.5 million in 2022, then spiked by 130.12% to $173.7 million in 2023, then surged by 58.44% to $275.2 million in 2024, then surged by 43.22% to $402.6 million in 2025.
  • Its Cash & Current Investments stands at $402.6 million for Q3 2025, versus $257.4 million for Q2 2025 and $263.2 million for Q1 2025.